WSJ
18 Nov 2026, 07:43 UTC · 1h ago
GSK Gets FDA Approval for New Lung-Cancer Drug
Impact · against what's priced in
GSK's FDA approval for a new lung cancer drug provides a positive growth catalyst for 2027. The move expands the company's footprint in a high-mortality disease area, promising new revenue streams in the U.S. market.
- GSK+0.60
No priced-in read yet
- In context
FDA approval for a new lung cancer medicine allows GSK to launch in the U.S., with revenue expected to impact the P&L starting in Q1 2027.
Read from the article alone
- Actual

Search tags




